Research programme: interleukin-4 antagonists - Fournier/Zambon

Drug Profile

Research programme: interleukin-4 antagonists - Fournier/Zambon

Alternative Names: IL-4 antagonists - Fournier/Zambon

Latest Information Update: 14 Aug 2007

Price : $50

At a glance

  • Originator Laboratoires Fournier; Zambon Group SpA
  • Developer Zambon Group SpA
  • Class
  • Mechanism of Action Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hypersensitivity; Respiratory tract disorders

Most Recent Events

  • 02 May 2002 Preclinical trials in Allergy in Switzerland (unspecified route)
  • 02 May 2002 Preclinical trials in Respiratory tract disorders in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top